Skip to main content

Stereotaxis, Inc.

STXS
Exchange
NYSE
Industry
Electromedical & Electrotherapeutic Apparatus
SEC CIK
0001289340

In the last 90 days, Stereotaxis, Inc. insiders filed 3 open-market purchases and 0 sales; 101 institutions reported holding it in 13F filings for Q3 2026, worth $50.4M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 17, 2026, 2:20 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: $21.6M (66.8% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Stereotaxis, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 9, 2026Mar 3, 2025Mar 4, 2024Mar 3, 2023Mar 3, 2022
Revenue$32.4M$26.9M$26.8M$28.1M$35.0M
Cost of revenue$15.3M$12.3M$11.9M$9.68M$11.8M
Gross profit$17.1M$14.6M$14.9M$18.5M$23.2M
Operating expenses$39.2M$39.3M$36.7M$37.2M$36.1M
Research and development$9.38M$9.76M$10.3M$10.6M$10.2M
Selling, general and administrative$17.8M$17.2M$14.1M$14.4M$14.0M
Operating income-$22.1M-$24.7M-$21.8M-$18.8M-$12.9M
Net income-$21.6M-$24.0M-$20.7M-$18.3M-$10.7M
EPS, basic$-0.25$-0.30$-0.27$-0.26$-0.16
EPS, diluted$-0.25$-0.30$-0.27$-0.26$-0.16
Weighted shares, basic91.0M85.2M80.7M76.1M75.6M
Weighted shares, diluted91.0M85.2M80.7M76.1M75.6M
Margins and growth
Gross margin52.7%54.2%55.5%65.6%66.3%
Operating margin-68.3%-91.9%-81.6%-66.7%-36.8%
Net margin-66.8%-89.3%-77.4%-65.0%-30.6%
Revenue growth, year over year+20.3%+0.5%−4.9%−19.6%+31.5%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Stereotaxis, Inc., annual
Line itemFY2025!FY2024!FY2023!FY2022!FY2021!
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 9, 2026Mar 3, 2025Mar 4, 2024Mar 3, 2023Mar 3, 2022
Cash and equivalents$13.4M$12.2M$19.8M$8.59M$38.7M
Short-term investments–––$19.8M–
Accounts receivable$5.85M$3.82M$3.82M$5.09M$5.41M
Inventory$9.57M$8.33M$8.43M$7.88M$4.43M
Total current assets$33.8M$26.4M$33.3M$43.2M$51.4M
Property, plant and equipment$3.02M$3.57M$3.30M$3.83M$2.63M
Goodwill$3.76M$3.76M–––
Intangible assets$6.43M$7.36M–––
Total assets$52.3M$46.7M$41.9M$53.4M$61.0M
Accounts payable$4.77M$5.67M$3.19M$3.27M$4.19M
Total current liabilities$22.4M$21.6M$13.2M$14.3M$13.3M
Total liabilities$33.5M$35.3M$20.0M$21.5M$21.6M
Shareholders' equity$13.5M$6.08M$16.3M$26.3M$33.8M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Stereotaxis, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 9, 2026Mar 3, 2025Mar 4, 2024Mar 3, 2023Mar 3, 2022
Operating cash flow-$13.7M-$8.50M-$9.14M-$8.41M-$2.95M
Capital expenditures$93.0K$34.0K$366.0K$2.38M$1.40M
Free cash flow-$13.8M-$8.53M-$9.51M-$10.8M-$4.34M
Stock-based compensation$9.85M$10.3M$10.6M$10.6M$9.36M
Dividends paid$0$0$0$0$0
Investing cash flow-$93.0K$74.0K$19.8M-$22.1M-$1.40M
Financing cash flow$14.8M$297.0K$81.0K$220.0K$547.4K
Net change in cash$985.0K-$8.13M$10.7M-$30.3M-$3.80M
Ratio
Stock-based compensation, % of revenue30.4%38.1%39.7%37.6%26.7%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Stereotaxis, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 31, 2026100.9M+8.1%SEC
Jul 31, 2026100.2M+10.5%SEC
Apr 30, 202697.7M+13.6%SEC
Feb 28, 202697.2M+13.1%SEC
Oct 31, 202593.3M+10.1%SEC
Jul 31, 202590.7M+7.1%SEC
Apr 30, 202586.0M+4.1%SEC
Feb 28, 202586.0M+4.7%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.